Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genomic landscape and therapeutic implications of Anaplastic Lymphoma Kinase fusion-positive colorectal cancer.

The oncologist - 6 Aug 2026

Li Xuanyi, Yasin Faiza, Pavlick Dean C, Ross Jeffrey S, Cecchini Michael

Abstract excerpt

BACKGROUND: Anaplastic lymphoma kinase (ALK) fusions are established oncogenic drivers and therapeutic targets in multiple malignancies, including non-small cell lung cancer, but are rare in colorectal cancer (CRC). Although ALK fusions in CRC have been associated with sensitivity to ALK inhibitors, their broader genomic context remains incompletely defined. We aimed to characterize the prevalence, clinicogenomic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Anaplastic Lymphoma Kinase
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Colorectal Neoplasms

Share to Genomics

Share to High-Throughput Nucleotide Sequencing

Share to Microsatellite Instability

Share to Oncogene Proteins, Fusion

Source

Open in PubMed Open full text

Identifiers

PMID: 42565556
DOI: 10.1093/oncolo/oyag308
PMCID: PMC13466715

Genes

ALK
APC
KRAS
PIK3CA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genomic landscape and therapeutic implications of Anaplastic Lymphoma Kinase fusion-positive colorectal cancer.PMID 42565556Read ↗

Colorectal Adenocarcinomas Harboring ALK Fusion Genes: A Clinicopathologic and Molecular Genetic Study of 12 Cases and Review of the Literature.Semantic proximity Read ↗

Molecular Characterization and Therapeutic Targeting of Colorectal Cancers Harboring Receptor Tyrosine Kinase FusionsSemantic proximity Read ↗

Pan-tumor survey of RET fusions as detected by next-generation RNA sequencing identified RET fusion positive colorectal carcinoma as a unique molecular subsetSemantic proximity Read ↗

ALK Fusions in a Wide Variety of Tumor Types Respond to Anti-ALK Targeted Therapy.Semantic proximity Read ↗

Oncogenic <i>ALK</i> Fusion in Rare and Aggressive Subtype of Colorectal Adenocarcinoma as a Potential Therapeutic TargetSemantic proximity Read ↗

Comprehensive genomic profiling reveals prognostic signatures and insights into the molecular landscape of colorectal cancerSemantic proximity Read ↗

Identification and characterization of RET fusions in advanced colorectal cancer.Semantic proximity Read ↗

Gene fusions and oncogenic mutations in MLH1 deficient and BRAFV600E wild-type colorectal cancers.Semantic proximity Read ↗

Comprehensive analysis of oncogenic fusions in mismatch repair deficient colorectal carcinomas by sequential DNA and RNA next generation sequencing.Semantic proximity Read ↗

Comprehensive Analysis of Oncogenic Fusions in Mismatch Repair Deficient Colorectal Carcinomas by Sequential DNA and RNA Next Generation SequencingSemantic proximity Read ↗

Colorectal Carcinomas Containing Hypermethylated MLH1 Promoter and Wild-Type BRAF/KRAS Are Enriched for Targetable Kinase FusionsSemantic proximity Read ↗

BRAF fusions define therapeutic vulnerability and tyrosine kinase inhibitor resistance in non-small cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.